CAS: 37693-01-9; 2-(2,4-Dichlorobenzyl)-4-(2,4,4-Trimethylpentan-2-yl)Phenol

该化合物是一种有机化合物,被归类为酚衍生物,主要因其抗微生物特性而得到承认;在制药和农业部门,它经常被用作抗菌剂;氯氟化碳针对各种真菌和细菌,展示了广泛的活动,使其在治疗感染和保存产品方面很有价值;该化合物的特点是能够扰乱微生物细胞膜,导致细胞死亡; 就物理特性而言,氯氟化碳通常是白到白的晶状固体,其有机溶剂中含有中度溶液,水溶性有限;其化学结构包括多种功能组群,有助于其生物活动;在与氯氟化碳合作时,安全和处理预防措施至关重要,因为如果摄入或吸入,可能会对健康造成危害; 进行了监管评估,以评估其安全状况,特别是在消费产品中使用情况;

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-9327264-B2
    优先权日:2011-01-31
    标 题 :Containerless synthesis of amorphous and nanophase organic materials
    发明人:BENMORE CHRIS J; WEBER JOHANN R
    权利人:BENMORE CHRIS J; WEBER JOHANN R; UCHICAGO ARGONNE LLC
    摘要:The invention provides a method for producing a mixture of amorphous compounds, the method comprising supplying a solution containing the compounds; and allowing at least a portion of the solvent of the solution to evaporate while preventing the solute of the solution from contacting a nucleation point. Also provided is a method for transforming solids to amorphous material, the method comprising heating the solids in an environment to form a melt, wherein the environment contains no nucleation points; and cooling the melt in the environment.

    专利号:US-2023322787-A1
    优先权日:2020-08-12
    标 题 :Process for preparing enantiomerically enriched jak inhibitors
    发明人:WIEDEMANN SEAN; COWDEN CAMERON J; BAZINET PATRICK; KAVOURIS KATHRYN E; WU KUO-MING; LEWIS ROBERT S
    权利人:CONCERT PHARMACEUTICALS INC
    摘要:Certain aspects of the present invention are directed to improved processes for preparing enantiomerically enriched intermediates for the synthesis of ruxolitinib and deuterated forms of ruxolitinib. Certain aspects are also directed to deuterated intermediates useful in the synthesis of deuterated forms of ruxolitinib. Certain aspects are also directed to reaction mixtures for preparing enantiomerically enriched intermediates useful in the synthesis of ruxolitinib and deuterated forms of ruxolitinib.

    专利号:WO-0032619-A1
    优先权日:1998-11-30
    标题:Methods and compositions for identification of inhibitors of ribosome assembly
    发明人:DAMMEL CAROL S; WATSON JULIE C
    权利人:RIBOGENE INC
    摘要:The invention provides a means for identifying novel antibiotics by screening for compounds that inhibit bacterial ribosome assembly and ribosomal protein synthesis, which comprises the screening of test compounds to identify those that inhibit the activity of a bacterial ribosomal protein. The in vitro and in vivo assays detect (a) increased translation of a reporter mRNA that is normally repressed in the presence of a ribosomal protein, (b) increased growth in cells that over-express ribosomal protein, and (c) decreased binding of the ribosomal protein to its target RNA. The invention encompasses the (a) methods of screening and testing compounds by the above methods, (b) compounds that are identified in the assay which inhibit ribosome assembly and protein synthesis and (c) methods for treatment using said compounds.

    专利号:US-2012197005-A1
    优先权日:2011-01-31
    标题 :Containerless synthesis of amorphous and nanophase organic materials

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Aherfi S, Pradines B, Devaux C, Honore S, Colson P, Scola B, Raoult D. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiol. 2021 Nov;16:1341-1370. doi: 10.2217/fmb-2021-0019. Epub 2021 Nov 10.
    2: Lee J, Stone J, Desai P, Kosowicz JG, Liu JO, Ambinder RF. Arsenicals, the Integrated Stress Response, and Epstein-Barr Virus Lytic Gene Expression. Viruses. 2021 Apr 30;13(5):812. doi: 10.3390/v13050812.
    3: Bailly C, Vergoten G. A new horizon for the old antibacterial drug clofoctol. Drug Discov Today. 2021 May;26(5):1302-1310. doi: 10.1016/j.drudis.2021.02.004. Epub 2021 Feb 10. 93(20):e00998-19. doi: 10.1128/JVI.00998-19.

    合成参考文献


    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知